Rotigotine in the treatment of Parkinson's disease. A study on a sample of 150 patients;Rotigotina en el tratamiento de la enfermedad de Parkinson. Experiencia sobre una muestra de 150 pacientes

Revista de Neurologia

Volumn 46, Issue 5, 2008, Pages 257-260

  Ruiz Huete, C ^a   Bermejo, Pedro Emilio ^a,b   Terron C ^a   Anciones, B ^a  

^a Hospital de la Zarzuela   (Spain)

^b Sanatorio Nuestra Senora del Rosario   (Spain)

Author keywords

Dopaminergic agonists; Parkinson's disease; Pramipexole; Ropinirole; Rotigotine

Indexed keywords

BENSERAZIDE; CABERGOLINE; CARBIDOPA; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; ROTIGOTINE; SELEGILINE;

ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DATA BASE; DROWSINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG WITHDRAWAL; DYSKINESIA; ERYTHEMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PARKINSON DISEASE; UNSPECIFIED SIDE EFFECT;

EID: 41849106824     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4605.2007617     Document Type: Article

References (32)

1. Jankovic J, Watts RL, Martin W, Boroojerdi B. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol 2007; 64: 676-82.
2. Kenney C, Jankovic J. Rotigotine transdermal patch in the treatment of Parkinson's disease and restless legs syndrome. Expert Opin Pharmacother 2007; 8: 1329-35.
3. The Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol 2003; 60: 1721-8.
4. Pahwa R, Factor SA, Lyons KE, Ondo WG, Gronseth G, Bronte-Stewart H, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66: 983-95.
5. Patton J, Neilson S, Boroojerdi B. Tolerability of switching from an oral dopamine agonist to transdermal rotigotine in Parkinson's disease [abstract]. Eur J Neurol 2006; 13: 217.
6. LeWitt PA, Boroojerdi B, MacMahon D, Patton J, Jankovic J. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease. Clin Neuropharmacol 2007; 30: 256-65.
7. Jankovic J, Watts RL, Martin W, Boroojerdi B. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol 2007; 64: 676-82.
8. LeWitt PA, Lyons KE, Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 2007; 68: 1262-7.
9. Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007; 68: 272-6.
10. Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH, SP513 Investigators. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007; 22: 2398-404.
11. Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007; 6: 513-20.
12. Poewe W, Giladi N, Boothman B. Rotigotine transdermal system in patients with advanced-stage Parkinson's disease as adjunctive therapy to levodopa: results of a placebo- and pramipexole-controlled trial. Mov Disord 2006; 21: 48.
13. Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004; 61: 1044-53.
14. Braun M, Cawello W, Poole K. Steady-state pharmacokinetics of rotigotine in patients with early-stage Parkinson's disease. Eur J Neurol 2005; 12: 37.
15. Scheller D, Kehr J. Continuous stimulation of dopamine receptors by continuous delivery of rotigotine in a rat model. J Neurol Sci 2005; 238: 369.
16. Metman LV, Gillespie M, Farmer C, Bibbiani F, Konitsiotis S, Morris M, et al. Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease. Clin Neuropharmacol 2001; 24: 163-9.
17. Widnell K. Pathophysiology of motor fluctuations in Parkinson's disease. Mov Disord 2005; 20: 17-22.
18. Naidu Y, Chaudhuri KR. Transdermal rotigotine: a new non-ergot dopamine agonist for the treatment of Parkinson's disease. Expert Opin Drug Deliv 2007; 4: 111-8.
19. Kehr J, Hu XJ, Goiny M, Scheller DK. Continuous delivery of rotigotine decreases extracellular dopamine suggesting continuous receptor stimulation. J Neural Transm. 2007;114:1027-31.
20. Olanow CW, Obeso JA, Stocchi F. Drug insight: continuous dopaminergic stimulation in the treatment of Parkinson's disease. Nat Clin Prac Neurol 2006; 2: 382-92.
21. Giménez-Roldán S. Ropinirol: un nuevo agonista dopaminérgico en el tratamiento de la enfermedad de Parkinson. Neurologia 1997; 12: 354-61.
22. Korczyn AD. Transdermal therapy in Parkinson's disease. Lancet Neurol 2007; 6: 475-6.
23. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000; 284: 1931-8.
24. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000; 342: 1484-91.
25. Donner B, Zenz M, Strumpf M, Raber M. Long-term treatment of cancer pain with transdermal fentanyl. J Pain Symptom Manage 1998; 15: 168-75.
26. Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol 2003; 2: 107-16.
27. Nyholm D. Pharmacokinetic optimisation in the treatment of Parkinson's disease: an update. Clin Pharmacokinet 2006; 45: 109-36.
28. Giladi N, Boroojerdi B. Rotigotine transdermal patch for the treatment of early morning and night time motor symptoms in patients with idiopathic Parkinson's disease. Mov Disord 2007; 22: 68.
29. Leopold NA, Polansky M, Hurka MR. Drug adherence in Parkinson's disease. Mov Disord 2004; 19: 513-7.
30. Grosset KA, Reid JL, Grosset DG. Medicine-taking behavior: implications of suboptimal compliance in Parkinson's disease. Mov Disord 2005; 20: 1397-404.
31. Durán-Ferreras E, Martínez-Parra C, Durán-Quintana JA. Medicamentos transdérmicos en neurología. Neurologia 2007; 22: 416.
32. Yang LP, Keating GM. Rivastigmine transdermal patch: in the treatment of dementia of the Alzheimer's type. CNS Drugs 2007; 21: 957-65.